20/20 BioLabs has signed an exclusive U.S. license agreement with ROKIT Healthcare to integrate ROKIT's advanced chronic kidney disease (CKD) prediction algorithm into its OneTest for Longevity platform. This integration expands 20/20's biomarker-based disease risk assessments, aiming to provide earlier detection and personalized risk insights for CKD, which affects over 35 million Americans. The partnership also includes shared marketing costs and potential future commercialization rights for 20/20's platform in East Asia. This move strengthens 20/20's position in the longevity analytics market by combining AI-powered biomarker tracking with regenerative health technologies to improve patient outcomes.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
